Ligand Pharmaceuticals Cash Flow Statement

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 30, 2021	Dec '20 Dec 30, 2020	2015 - 2019
Net Income	0.06	0.16	0.09	0.12	-1.2	Upgrade
Loss (Gain) From Sale of Investments	0.29	0.05	0.06	0.02	0.89	Upgrade
Other Operating Activities	-0.41	-0.4	-0.3	-0.9	0.18	Upgrade
Change in Accounts Receivable	-0	-	0.01	0	-0.01	Upgrade
Change in Accounts Payable	-0	-0.04	0.08	0.11	0.04	Upgrade
Change in Other Net Operating Assets	-	-	-	0.35	-	Upgrade
Operating Cash Flow	-0.06	-0.04	-0.06	-0.29	-0.1	Upgrade
Repurchase of Common Stock	-	-	-	-	0.41	Upgrade
Other Financing Activities	0.05	0.06	0.02	0.25	-2.3	Upgrade
Financing Cash Flow	0.05	0.06	0.02	0.25	-1.89	Upgrade
Net Cash Flow	-0.01	0.02	-0.04	-0.04	-1.99	Upgrade
Free Cash Flow	-0.06	-0.04	-0.06	-0.29	-0.1	Upgrade
Free Cash Flow Margin	-	-20.09%	-31.35%	-137.02%	-	Upgrade
Free Cash Flow Per Share	-0.00	-	-0.00	-0.00	-0.00	Upgrade
Levered Free Cash Flow	-0.15	-0.09	0.24	0.26	-2.97	Upgrade
Unlevered Free Cash Flow	-0.15	-0.09	0.24	0.26	-2.92	Upgrade
Change in Net Working Capital	0.1	0.1	-0.21	-0.23	2.23	Upgrade

Updated Oct 2, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.